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Introduction
Obesity is an increasingly serious global problem, not
only for the harm it causes in its own right, but also due
to the associated health threats, especially type 2 dia-
betes, systemic hypertension, cardiovascular disease,
certain cancers, asthma, and sleep apnea.1–3 The preva-
lence of obesity has been steadily increasing in children
and adolescents in recent years,4–6 which suggests the
likelihood of worsening obesity trends in the future
adult population. Therefore, it is essential to develop
ways of preventing more people from becoming obese.
However, diet and physical exercise are usually not very
effective, and most patients regain weight even after
successful weight loss.7 Thus, treatment might be nec-
essary when prevention fails.8
The significant progress in unveiling the molecular
mechanisms of body weight regulation has provided
potential therapeutic targets for obesity.9,10 For a drug
to have a significant impact on body weight, it must
ultimately affect energy intake and/or expenditure.9
The development of inhibitors of nutrient digestion
and absorption, which reduce energy intake through
gastrointestinal mechanisms without altering any cen-
tral mechanisms, is one of the most important strategies
in the treatment of obesity.11
Dietary lipids represent the major source of
unwanted calories;12,13 therefore, lipid metabolism is
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a vital and subtle balance that maintains energy homeo-
stasis.14 Once this balance is lost, obesity or hyperlipid-
emia develops, followed by a series of severe diseases,
including atherosclerosis, hypertension, diabetes, and
dysfunction of certain organs. Obviously, drug control
of lipid metabolism offers a possible way to prevent or
treat these diseases. The identification and characteri-
zation of several enzymes involved in lipid metabolism
have yielded a rich pool of potential targets for drugs to
treat obesity and other metabolic disorders.14 Pancreatic
lipase, the main lipid-digesting enzyme, removes fatty
acids from the α and α position of dietary triglycerides,
which yields the lipolytic product β-monoglyceride and
long-chain saturated and polyunsaturated fatty acids.
Inhibition of pancreatic lipase is an attractive targeted
approach for the treatment of obesity.13 For instance,
orlistat, a hydrogenated derivative of lipstatin, which
is obtained from Streptomyces toxytricini, is the only
pancreatic lipase inhibitor currently approved for long-
term treatment of obesity. Its use can result in up to
10% weight loss when used in combination with dietary,
behavioral and exercise therapy,15 but it also has
unpleasant and non-negligible side effects.9 Therefore,
there is a need for more lipase inhibitors or medicinal
products that are safe and effective.
Naturally occurring phytochemicals present an excit-
ing opportunity for the discovery of newer anti-obesity
agents. Some have already been identified as lipase inhi-
bitors, e.g. licochalcone A, which has been isolated from
the roots of Glycyrrhiza uralensis,16 platycodin D from
the fresh roots of Platycodon grandifloru,17 dioscin
from Dioscorea nipponica,18 phenolic constituents from
the leaves of Nelumbo nucifera,19 and other components
from other kinds of herbs. However, it remains neces-
sary to search for more efficacious lipase inhibitors from
traditional Chinese herbs. Here, we studied 37 Chinese
herbs for their lipase inhibitory activity using 2,4-
dinitrophenyl butyrate (DNPB) as an artificial substrate.
Methods
Plant materials and chemicals
All traditional Chinese medicinal herbs were purchased
from Qian Kun Drugstore of Yangling, a Chinese herb
store in China. A collection of voucher specimens is
available for confirmation in the Research Centre for
Natural Medicinal Chemistry, Northwest Agriculture &
Forestry University, Yangling, Shaanxi, China.
Porcine pancreatic lipase (PPL, type II) and orlistat
were purchased from Sigma-Aldrich (St Louis, MO,
USA). Quercetin, rutin, catechin, and luteolin were
all purchased from Indofine (Hillsborough, NJ, USA).
Emodin and ursolic acid were purchased from Fluka
Chemie (Buchs, Switzerland). All other chemicals and
solvents were of analytical grade.
Preparation of plant extracts
The Chinese herbs were air dried and ground into fine
powder. The powdered material (50 g) was ultrason-
ically extracted with 500 mL methanol 3 times at room
temperature, and concentrated at 45°C in a rotator
vacuum evaporator (Buchi, Flawil, Switzerland). The
final extracts were stored at −20°C.
PPL inhibition assay
Lipase activity was measured using DNPB as a sub-
strate.16 DNPB was synthesized using the method
previously described by Mosmuller et al.20 PPL stock
solutions (1 mg/mL) were prepared in 0.1 mM potas-
sium phosphate buffer (pH 6.0), and the solutions were
stored at −20°C. To determine lipase inhibitory activity,
the extracts (0.2 mg/mL) or phytochemicals (at differ-
ent concentrations) were pre-incubated with the enzyme
for 1 hour in potassium phosphate buffer (0.1 mM,
pH 7.2, combined with 0.6mL/100mL Tween 80) at
30°C before assaying the enzyme activity.21 The reac-
tion was then started by adding 0.1mL 25mM DNPB,
all in a final volume of 5.0mL. After incubation at 30°C
for 5 minutes, the amount of 2,4-dinitrophenol released
in the reaction was measured at 360 nm using the
Evolution 300UV-Visible spectrophotometer (Thermo
Fisher Scientific, Waltham, MA, USA). The activity of
the negative controls was also checked with and with-
out inhibitor. The inhibitory activity (I) was calcu-
lated according to the following formula:22
where A is the activity of the enzyme without inhibitor,
a is the negative control without inhibitor, B is the activ-
ity of the enzyme with inhibitor, and b is the negative
control with inhibitor.
Statistical analysis
All results were expressed as median ± standard devia-
tion (n = 3). Significance of difference from the control
was determined by Duncan’s test and Kruskal–Wallis
test, and a p value < 0.05 was considered significant.
Results
Anti-lipase activity of crude herbal extracts
Thirty-seven extracts were prepared from selected parts
of the traditional Chinese herbal medicines and were
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Chinese herbs with anti-lipase activity
Table 1. Lipase inhibitory effects of various Chinese herbs
No. Scientific name Plant part Family Inhibition (%)*
1 Achyranthes bidentata Bl. Root Amaranthaceae 2.9 ± 3.5
2 Alisma oriental (Sam.) Juzep. Tuber Alismataceae 15.4 ± 0.0
3 Angelica sinensis (Oliv.) Diels. Root Umbelliferae 1.2 ± 1.9
4 Astragalus membranaceus (Fisch.) Bunge Root Leguminosae −11.0 ± 2.2
5 Atractylodes macrocephala Koidz. Rhizome Asteraceae –3.1 ± 3.8
6 Bupleurum chinense DC. Root Umbelliferae 16.8 ± 4.2
7 Carthamus tinctorius L. Flower Asteraceae 12.3 ± 3.5
8 Citrus aurantium L. Young fruit Rutaceae −3.5 ± 2.4
9 Cornus officinalis Sieb. Et Zucc. Fruit Cornaceae 7.6 ± 3.8
10 Dioscorea opposita Thunb. Rhizome Dioscoreaceae 3.5 ± 3.9
11 Eclipta prostrata L. Whole grass Asteraceae −3.1 ± 0.3
12 Ephedra sinica Stapf Herbaceous stem Ephedraceae 25.9 ± 4.3
13 Epimedium brevicornum Maxim. Aerial part Berberidaceae −3.8 ± 1.9
14 Forsythia suspensa (Thunb.) Vahl Fruit Oleaceae 20.4 ± 4.9
15 Grataegus pinnatifida Bunge Fruit Rosales 11.3 ± 0.1
16 Leonurus japonicus Houtt. Fruit Labiatae 11.1 ± 5.2
17 Ligusticum chuanxiong Hort. Rhizome Umbelliferae 16.3 ± 5.6
18 Ligustrum lucidum Ait. Fruit Oleaceae 8.0 ± 2.2
19 Millettia reticuiata Benth. Rattan cane Leguminosae 33.3 ± 4.2
20 Morus alba L. Ear Moraceae 16.4 ± 3.2
21 Paeonia lactiflora Pall. Root Ranunculaceae 2.8 ± 0.1
22 Panax notoginseng (Burk.) F.H.Chen Root Araliaceae −4.3 ± 5.1
23 Phragmites communis Trin. Rhizome Poaceae −5.4 ± 0.7
24 Pinellia ternata (Thunb.) Breit. Tuber Araceae −8.1 ± 2.7
25 Plantago asiatica Linn. Whole grass Plantaginaceae 0.7 ± 1.0
26 Polygonum cuspidatum Sieb. et Zucc. Root and rhizome Polygonaceae 37.8 ± 6.5
27 Polygonum multiflorum Thunb. Root Polygonaceae 17.0 ± 3.9
28 Portulaca oleracea Linn. Aerial part Portulacaceae 6.0 ± 3.7
29 Prunella vulgaris L. Ear Labiatae 74.7 ± 10.0
30 Pueraria lobata (Willd.) Ohwi Root Leguminosae −15.9 ± 2.4
31 Raphanus sativus L. Seed Cruciferae 3.0 ± 1.3
32 Rheum palmatum L. Root and rhizome Polygonaceae 53.8 ± 9.0
33 Salvia miltiorrhiza Bge. Root and rhizome Labiatae 32.7 ± 3.8
34 Saposhnikovia divaricata (Turcz.) Schischk. Root Umbelliferae −1.9 ± 2.1
35 Sophora tonkinensis Gapnep. Root and rhizome Leguminosae 2.8 ± 3.4
36 Taxillus chinensis (DC.) Danser Aerial part Loranthaceae 21.1 ± 5.1
37 Uncaria macrophylla Wall. Aerial part Alismataceae 30.1 ± 3.3
38 Orlistat 93.5 ± 7.3
*p < 0.05 compared with control orlistat, data presented as median ± standard deviation (n = 3), and “−” indicates a promotion of lipase activity. The final con-
centration of the extracts used in this screening was 200 mg/mL.
tested at a concentration of 0.2 mg/mL for PPL inhi-
bition (Table 1). The selected Chinese herbs, which
belonged to various families, had different effects on
PPL in vitro. Six extracts showed moderate to strong
anti-lipase activity (> 30%).
Among these 6 plants, Prunella vulgaris L. (Labiatae)
and Rheum palmatum L. (Polygonaceae), were found
to have strong inhibitory activity of >50% against PPL:
74.7% with P. vulgaris, and 53.8% with R. palmatum.
Millettia reticulata Benth. (Leguminosae), Polygonum
cuspidatum Sieb. et Zucc. (Polygonaceae), Salvia mil-
tiorrhiza Bge. (Labiatae), and Uncaria macrophylla
Wall. (Alismataceae) showed > 30% inhibition of PPL.
Additionally, there were several herbs that displayed
weak inhibitory activity against PPL. Some of the
herbs slightly promoted the activity of PPL, such as
Pueraria lobata (Willd.) Ohwi (Leguminosae), which
increased the activity of the enzyme by 15.9%, which
was distinct from the other herbs.
The crude extracts of P. vulgaris and R. palmatum
at different concentrations were also tested for their
PPL inhibitory effects, and a dose–response curve was
obtained (Figure 1). To avoid inaccurate test results,
extracts with a concentration > 200 μg/mL were not
tested for a sudden increase in ultraviolet absorption
from the extracts themselves. With weaker effects than
the positive control orlistat at each concentration,
both P. vulgaris and R. palmatum exhibited increasing
inhibitory activities as concentration rose from 5 to
200 μg/mL.
Anti-lipase activity of coexistent or
phytochemicals appearing at high levels in
promising herbs
The anti-lipase activity of the coexistent phytochemicals
or phytochemicals found at high levels in the 3 most
promising Chinese herbs (Table 2) were also tested,
and the results are shown in Table 3.
All the chemicals tested displayed increasing inhi-
bition of PPL with increasing concentration. We tried
to determine their activity at 3 different concentrations
(25 μg/mL, 50 μg/mL and 100 μg/mL), but some
could not be tested because of too large an absorbance
from the chemicals, which could have resulted in inac-
curate data. Thus, lower concentrations (5 μg/mL and
10 μg/mL) were also used when the data for higher
concentrations were unavailable.
Quercetin, which is present in P. vulgaris and Pol.
cuspidatum, exhibited a good inhibitory effect (27.4%)
on PPL at a concentration of 25 μg/mL. Luteolin,
another phytochemical that coexists in these 2 herbs,
had an inhibitory activity of 17.3% at the same con-
centration. Ursolic acid also contributed to a better per-
formance of these 2 herbs, with an anti-lipase activity of
11.0%. For P. vulgaris, the effect might also have been
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Figure 1. Porcine pancreatic lipase inhibitory activities of Prunella
vulgaris L. and Rheum palmatum L. Orlistat was used as a posi-
tive control.
Table 2. Coexistent phytochemicals or phytochemicals present at high levels in the most promising Chinese herbs for porcine pancreatic
lipase activity
Chinese herbs
Phytochemicals
Luteolin Rutin Catechin Quercetin Ursolic acid Emodin
Prunella vulgaris L. * * * *
Rheum palmatum L. * * *
Polygonum cuspidatum Sieb. et Zucc. * * * * *
*Indicates the existence of a compound in the corresponding herb.
Table 3. Inhibitory effects (%) of coexistent phytochemicals or phytochemicals present at high levels in promising Chinese herbs for
porcine pancreatic lipase activity*
Phytochemical Formula Hazard†
Concentration (μg/mL)
5 10 25 50 100
Luteolin C15H10O6 Irritant 1.7 ± 0.6‡ 10.9 ± 1.8‡ 17.3 ± 1.4‡ NT NT
Rutin C27H30O16 Harmful NT NT 11.0 ± 2.0‡ 24.4 ± 2.7‡ 30.8 ± 1.2‡
Catechin C15H14O6 Irritant NT NT 4.2 ± 0.9‡ 8.3 ± 0.3‡ 6.5 ± 1.5‡
Quercetin C15H10O7 Toxic 6.9 ± 0.7‡ 18.1 ± 2.1‡ 27.4 ± 2.9‡ NT NT
Ursolic acid C30H48O3 –§ NT NT 11.0 ± 1.0‡ 22.6 ± 1.9‡ 39.6 ± 2.7‡
Emodin C15H10O5 Irritant 1.5 ± 0.6‡ 4.7 ± 0.8‡ 12.0 ± 1.3‡ NT NT
Orlistat C29H53NO5 –§ 40.7 ± 0.8 63.9 ± 1.7 87.1 ± 2.5 91.3 ± 2.9 92.0 ± 3.3
*Data (%) are presented as median ± standard deviation (n = 3); †adapted from the product information at http://www.sigmaaldrich.com; ‡p < 0.05 compared
with positive control orlistat; §non-toxic and comparatively safe. NT = not tested.
enhanced by rutin, which exhibited an activity similar
to that of ursolic acid.
Discussion
Besides a wide range of health benefits, extracts of 
P. vulgaris have recently been reported to have an anti-
hyperglycemic enhancing effect in diabetic mice,23 and
extracts of R. palmatum have been used to treat hyper-
lipidemia in diabetic rats.24 Emodin, one of the main
effective components in R. palmatum and Pol. cuspi-
datum, can not only inhibit cell differentiation and pro-
liferation of 3T3-L1 preadipocytes,25 but also promotes
adipocyte differentiation in 3T3-L1 cells.26 In the cur-
rent study, emodin showed an anti-lipase activity of
12.0% at a concentration of 25 μg/mL, which suggests
that it can be used as an anti-obesity drug. Polydatin,
another important chemical in Pol. cuspidatum, has been
found to have lipid-lowering activity, and has favorable
potency for clinical development as a hypolipemic
and/or hepatoprotective agent.27,28 Our study indi-
cated that the methanol extracts of P. vulgaris and 
R. palmatum showed strong inhibitory effects against
PPL (> 50%), which suggests that these herbs could
be candidate anti-obesity drugs.
The anti-lipase properties of the crude herbal ex-
tracts might be determined not only by the species of
the phytochemicals, but also by their content in the
herbs. For example, emodin was not as active as quer-
cetin, but its high concentration contributed to the
activity of R. palmatum, which demonstrated that
emodin was mainly responsible for the anti-lipase
activity of R. palmatum.
For clinical research in obesity control, the toxicity
of the chemicals must be considered. Although quer-
cetin has much better anti-lipase activity than other
compounds at the same concentration, it is classified as
toxic. Therefore, it might not be a good candidate for
further clinical investigation, or structural modification
might be needed. Rutin is also harmful to humans.
Ursolic acid is relatively non-toxic, and has been used
in cosmetics and health products;29 thus, it could be a
much more promising candidate for management of
overweight or obesity.
Although good activities were detected from the
coexistent or phytochemicals present at high levels in
the top 3 promising Chinese herbs, we could not con-
clude whether or not these chemicals were the only
contributors to their excellent anti-lipase characteristics.
Thus, further investigations, both in vitro and in vivo,
should be conducted to elucidate the main effective
phytochemicals in these candidates, which are responsible
for the inhibition of lipase activity, using bioguided
fractionation.
For screening, especially when faced with a mass of
materials, the testing method used in the assay must be
easy to perform and reliable. There are many methods
for the determination of lipase activity, but not all of
them are well suited to screening because of the com-
plexity of the procedures. In our research, the synthetic
substrate DNPB was used, and it enabled the deter-
mination of the activity of PPL to be conducted easily
using a spectrophotometric method. Furthermore, a
positive control, orlistat, was used to ensure the reliabil-
ity of our results.
In conclusion, the screening of methanolic extracts
of 37 Chinese medicinal plants in vitro led to the iden-
tification of several extracts with potential anti-lipase
activity, in particular, P. vulgaris and R. palmatum. The
phytochemicals in the promising herbs also exhibited
good to moderate anti-lipase activity, but they might
not be the only contributors to the activity of the herbs.
Therefore, more studies should be carried out. To the
best of our knowledge, these traditional Chinese herbal
medicines and monomeric chemicals have not been
previously screened for their lipase inhibitory activity.
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